Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO
The drugmaker said efficacy and safety data didn't support further development of the drug, amlitelimab, for atopic dermatitis.
SNY - Sanofi
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$49.50
DETAILS
HIGH:
$50.00
LOW:
$49.00
MEDIAN:
$49.50
CONSENSUS:
$49.50
UPSIDE:
12.50%
Stock News
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews
Sanofi today announced discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis.
Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter
Sanofi evolves its Executive Committee to support its next strategic chapter Paris, July 21, 2026. Sanofi today announced an evolution of its Executive Committee, bringing together a focused leadership team across its businesses, scientific organization and key global functions as the company continues to deliver on its priorities and prepares its next strategic chapter.
AI Bubble Risks Make Dividend Stocks Attractive Again
I identify dividend stocks and REITs that could protect investors from AI bubble risks, geopolitics, and inflation while generating attractive income. My "ALLKA Dividend Rating" model separates quality dividend opportunities from yield traps by analyzing dividend sustainability, growth prospects, and valuation. The article explores three dividend strategies, "High-Yield Defensive," "Balanced Income," and "Pure Growth," designed for goals ranging from high yield to dividend growth.
Aqemia and Sanofi Expand Their Research Collaboration
PARIS & LONDON--(BUSINESS WIRE)-- #DrugDiscovery--Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and.
3 High-Yield Dividend Stocks to Buy and Hold
All three can be bought on the dip.
Press Release: Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
Sanofi's subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
US FDA approves Sanofi's wearable injector form of blood cancer drug
The U.S. Food and Drug Administration said on Friday it has approved Sanofi's blood cancer drug, Sarclisa, which can be given under the skin through a wearable injector, offering multiple myeloma patients a less burdensome alternative to intravenous infusions.
EU seeks feedback on Sanofi's commitments addressing suspected anti-competitive behaviour
The European Commission said on Wednesday it would seek feedback on commitments offered by French pharmaceutical company Sanofi to address concerns that it may have breached competition rules in a flu vaccine marketing campaign.
SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study
Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.
Press Release: Availability of the aide-mémoire for Q2 2026 results
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.
Bargain Hunters: These 3 High-Yielding Stocks Recently Hit New 52-Week Lows
When dividend stocks drop in value, investors have the opportunity to secure some higher-than-typical yields. The stocks listed here haven't been doing well this year, but they offer some attractive dividend income.
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
The European Commission opened on Friday an investigation into whether French drug giant Sanofi breached EU competition rules in a flu vaccine marketing campaign.
Is AbbVie a Buy After Its Purchase of Apogee?
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity
Sanofi is reiterated as a compelling buy, trading at a pronounced valuation discount versus pharma peers despite solid results and strategic focus. Dupixent drives 40% of Sanofi's sales and 80% of Q1 incremental growth; management is pursuing lifecycle management to mitigate 2031 U.S. LOE risk. Dupixent concentration is not unique. Management continues to pursue lifecycle management initiatives, including new formulations and a hyaluronidase co-formulation, while planning conservatively under a no-extension scenario.
Press Release: Sanofi Foundation opens new chapter centered on future generations
Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, particularly those living with serious diseases.
EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
Sanofi wins EU nod for Cenrifki in secondary progressive multiple sclerosis without relapses, while Wayrilz gets Japan nod for immune thrombocytopenia.
Sanofi Multiple Sclerosis Drug Gets EU Approval
The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.
Press Release: Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, June 23, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization to Wayrilz (rilzabrutinib), a novel oral reversible Bruton's tyrosine kinase inhibitor (BTKi), for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is considered to be problematic.
Price Targets
Sanofi price target lowered to $49 from $52 at Morgan Stanley
$49.00
(was $42.98)
Sarita Kapila
·
Morgan Stanley
Sanofi downgraded to Equal Weight from Overweight at Morgan Stanley
$52.00
(was $46.08)
Morgan Stanley
Sanofi downgraded to Neutral from Outperform at BNP Paribas
$50.00
(was $48.06)
Peter Verdult
·
BNP Paribas
Sanofi resumed with an Equal Weight at Morgan Stanley
$56.00
(was $49.19)
Sarita Kapila
·
Morgan Stanley
Sanofi price target raised to $64 from $56 at Berenberg
$64.00
(was $58.51)
Luisa Hector
·
Berenberg Bank
Sanofi-Aventis (SNY) PT Raised to $60 at Argus
$60.00
(was $52.53)
Jasper Hellweg
·
Argus Research
Sanofi-Aventis (SNY) PT Lowered to $55 at Argus, 'BUY as FDA reviews Dupixent for COPD'
$55.00
(was $48.00)
Jasper Hellweg
·
Argus Research
Sanofi confirms to Bloomberg Zantac settlement in California
$48.07
(was $48.17)
Iain Simpson
·
Barclays